MedWatch

Novo Nordisk gets obesity drug approved in Canada

The pharmaceutical company has received marketing authorization for Wegovy from Health Canada, it reports in a press release.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

The Canadian health agency, Health Canada, has approved Novo Nordisk's obesity drug Wegovy.

This was revealed in a press release on Thursday, which also stated that the company expects to launch the drug in the country in fall 2022.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs